eligibility_summary
Inclusion: 18–74, R/R MM after ≥3 lines (progressed during/≤12 mo of last), transplant‑ineligible, measurable disease, ECOG 0–2, survival ≥12 wks, adequate organs, dose‑expansion: BM BCMA ≥50%. Exclusion: prior BCMA or CAR‑T, allo‑HSCT or recent ASCT (≤12 wks), CNS disease, PCL/extramedullary MM/amyloidosis, serious comorbidity/infection, autoimmune/immunodeficiency on immunosuppression, other cancer ≤5 yrs, unresolved ≥G2 tox, pregnancy/lactation, steroids >5 mg/d, live vaccine ≤4 wks, Cy/Flu allergy, GVHD, substance abuse.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: CBG002 CAR‑T Cell Suspension—an autologous, genetically engineered cell therapy in which patient T cells are modified to express a chimeric antigen receptor targeting BCMA (TNFRSF17). Mechanism of action: CAR engagement of BCMA on myeloma cells drives MHC‑independent T‑cell activation (CD3ζ signaling with co‑stimulation), expansion, cytokine release, and perforin/granzyme‑mediated cytolysis of tumor cells. Targets: BCMA‑positive malignant plasma cells in multiple myeloma and the BCMA/BAFF/APRIL survival axis that supports plasma‑cell persistence. Trial design: Phase I, single‑arm, 3+3 dose escalation in relapsed/refractory MM, prior BCMA‑directed therapies excluded.